Topic: Tau-wild-type

Alzheimer’s disease is the leading cause of dementia among aging population. Currently accepted treatments are focused on the symptoms while efforts are made to the develop therapies that target the major pathological hallmarks i.e., β-amyloid (Aβ) plaques and hyperphosphorylated Tau tangles. Evidence from epidemiology and neuroimaging studies suggest that Type 2 Diabetes (T2DM) and Alzheimer's disease (AD) have a shared pathogenesis. Moreover, insulin resistance has been shown to impact hyperphosphorylation and aggregation of Tau making this an important risk factor for the detection of early